Insulet (PODD) Net Income towards Common Stockholders (2010 - 2026)
Insulet's (PODD) quarterly Net Income towards Common Stockholders came in at $91.1 million in Q1 2026, up 156.62% YoY from $35.5 million in Q1 2025, and down 10.42% on a QoQ basis from $101.7 million in Q4 2025.
Insulet (PODD) Net Income towards Common Stockholders (2010 - 2026) Analysis & Trends
Insulet (PODD) has 16 years of Net Income towards Common Stockholders data on file, last reported at $91.1 million in Q1 2026.
- Quarterly Net Income towards Common Stockholders rose 156.62% year-over-year to $91.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $302.9 million (down 24.71% YoY) and the FY2025 annual result came in at $247.1 million, down 40.93% from the prior year.
- Net Income towards Common Stockholders fell to $91.1 million in Q1 2026, from $101.7 million in the prior quarter.
- In the past five years, Net Income towards Common Stockholders ranged from a high of $188.6 million in Q2 2024 to a low of -$35.0 million in Q2 2022.
- A 5-year average of $56.9 million and a median of $51.5 million in 2024 frame the typical range for Net Income towards Common Stockholders.
- Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders plunged 141.27% — and 2023, when it surged 1098.08%.
- Tracing PODD's Net Income towards Common Stockholders over 5 years: stood at $17.0 million in 2022, then jumped by 508.24% to $103.4 million in 2023, then dropped by 2.61% to $100.7 million in 2024, then rose by 0.99% to $101.7 million in 2025, then decreased by 10.42% to $91.1 million in 2026.
- The last three Net Income towards Common Stockholders figures came in at $91.1 million (Q1 2026), $101.7 million (Q4 2025), and $87.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.07 Bn | 193.46 Bn | 7.27 Bn | 928.00 Mn |
| 2 | Stryker | 127.90 Bn | 124.43 Bn | 4.50 Bn | 1.28 Bn |
| 3 | Medtronic | 118.84 Bn | 109.62 Bn | 6.41 Bn | 1.26 Bn |
| 4 | Boston Scientific | 73.33 Bn | 72.79 Bn | 3.85 Bn | 907.00 Mn |
| 5 | Edwards Lifesciences | 51.93 Bn | 47.68 Bn | 1.35 Bn | 241.40 Mn |
| 6 | Dexcom | 34.46 Bn | 32.51 Bn | 830.00 Mn | 249.10 Mn |
| 7 | GE HealthCare Technologies | 33.91 Bn | 31.81 Bn | 2.18 Bn | 574.00 Mn |
| 8 | Koninklijke Philips | 26.36 Bn | 23.04 Bn | 4.55 Bn | 621.86 Mn |
| 9 | Steris | 23.12 Bn | 22.64 Bn | 684.20 Mn | 201.00 Mn |
| 10 | Insulet | 10.32 Bn | 9.79 Bn | 562.60 Mn | 95.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 95.00 Mn |
| Mar 31, 2026 | 91.10 Mn |
| Dec 31, 2025 | 101.70 Mn |
| Sep 30, 2025 | 87.60 Mn |
| Jun 30, 2025 | 22.50 Mn |
| Mar 31, 2025 | 35.50 Mn |
| Dec 31, 2024 | 100.70 Mn |
| Sep 30, 2024 | 77.50 Mn |
| Jun 30, 2024 | 188.60 Mn |
| Mar 31, 2024 | 51.50 Mn |
| Dec 31, 2023 | 103.40 Mn |
| Sep 30, 2023 | 51.90 Mn |
| Jun 30, 2023 | 27.30 Mn |
| Mar 31, 2023 | 23.80 Mn |
| Dec 31, 2022 | 17.00 Mn |
| Sep 30, 2022 | -5.20 Mn |
| Jun 30, 2022 | -35.00 Mn |
| Mar 31, 2022 | 27.80 Mn |
| Dec 31, 2021 | 29.20 Mn |
| Sep 30, 2021 | 12.60 Mn |